KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial.

Zhiming Li, Wenqi Jiang, Hui Zhou, Hong Cen, Mingzhi Zhang, Fangfang Lv, Qingyuan Zhang, Xiuhua Sun, Lihong Liu, Yunhong Huang, Haiyan Yang, Sujun Gao, Chuan He, Wei Yang, Wenyu Li, Ding Yu, Yu Yang, Ying Cheng, Zhengzi Qian, Ying Xiang, Qunyi Guo, Bing Xu, Yuqin Song, Liling Zhang, Lie Lin, Jianzhen Shen, Feng Yan, Huilan Liu, Donghua Zhang, Jishi Wang, Min Zhou, Xiongpeng Zhu, Weihua Zhang, Weili Zhao, Ru Feng, Xiaohong Zhang, Jie Jin, Meizuo Zhong, Mei Zhang, Jingbo Wang, Hongmei Jing, Zhao Wang, Hongguo Zhao, Jun Zhu

J Immunother Cancer 12(10) e008895

PMID39455094
PMCIDPMC11529747
DOI10.1136/jitc-2024-008895
发表日期2024-10-25
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

BACKGROUND: In patients with untreated CD20-positive diffuse large B-cell lymphoma (DLBCL), a phase 3 trial was carried out to evaluate the efficacy and safety of zuberitamab plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; Hi-CHOP) versus rituximab plus CHOP (R-CHOP) treatment regimens. METHODS: In a 2:1 ratio, eligible patients were assigned randomly to receive treatment of six cycles of either 375 mg/m2 zuberitamab or rituximab together with conventional CHOP chemotherapy. The objective response rate (ORR) at C6D50 served as the primary endpoint, and a non-inferiority margin of 10% was established. The secondary endpoints included the complete response (CR) rate at C6D50, duration of response (DOR), progression-free survival (PFS) and event-free survival (EFS) judged by blinded-independent review committee (BIRC), overall survival (OS) and safety outcomes. RESULTS: Of the 487 randomized patients, 423 patients including 287 in the Hi-CHOP and 136 in the R-CHOP groups completed the C6D50 assessment. For the full analysis set (FAS) and per-protocol set (PPS), BIRC-assessed ORR at C6D50 for the Hi-CHOP and R-CHOP groups were 83.5% versus 81.4% and 95.3% versus 93.7%, respectively. The non-inferiority was confirmed as the lower limit of the two-sided 95% CI for the intergroup differences of -5.2% and -3.3%; both were >-10% in the FAS and PPS. The BIRC-assessed CR rate of Hi-CHOP was significantly higher in PPS (85.7% vs 77.3%, p=0.038), but comparable in FAS (75.2% vs 67.9%, p=0.092). After a median follow-up of 29.6 months, patients in the Hi-CHOP group had a slight advantage with regard to the DOR (HR 0.74, p=0.173), PFS (HR 0.67, p=0.057), EFS (HR 0.90, p=0.517) and OS (HR 0.60, p=0.059). Patients with the germinal-center B cell-like subtype who received Hi-CHOP exhibited statistically significant improvements in ORR (p=0.034) and CR rate (p=0.038) at C6D50, EFS (p=0.046) and OS (p=0.014). Treatment-emergent adverse event occurrence rates were comparable across groups (all p>0.05). Infusion-related responses occurred more often in the Hi-CHOP group (32.1% vs 19.9%, p=0.006), all of grade 1-3 severity. CONCLUSIONS: Zuberitamab (375 mg/m2) plus CHOP was non-inferior to R-CHOP regarding ORR but exhibited a higher CR rate and was well tolerated in CD20-positive, previously untreated Chinese patients with DLBCL. TRIAL REGISTRATION NUMBER: Chinese Clinical Trial Registry, ChiCTR2000040602, retrospectively registered.

KM 提取结果

2 个 Figure · 8 个 KM 面板

进入结果中心
KM Figure4 个面板

Figure 2

Figure 2. Kaplan-Meier curves of BIRC-assessed efficacy outcomes for patients in the Hi-CHOP and R-CHOP groups (FAS). ( A ) Duration of response, ( B ) progression-free survival, ( C ) events-free survival, ( D ) overall survival. Note: The cut-off date for the analysis was August 31, 2022, with a median follow-up period of 29.6 months. BIRC, blinded independent review committee; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; FAS, full analysis set; Hi-CHOP, zuberitamab plus CHOP; NE, not evaluable; R-CHOP, rituximab plus CHOP.

A

Duration of response

Figure 2 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

Progression-free survival

Figure 2 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

Events-free survival

Figure 2 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:off origin start曲线 1:extreme upward reversal
查看结果
D

Overall survival

Figure 2 · Panel D

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel D 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure4 个面板

Figure 3

Figure 3. Kaplan-Meier curves of the BIRC-assessed efficacy outcomes for GCB patients in the Hi-CHOP and R-CHOP groups (FAS). ( A ) Duration of response, ( B ) progression-free survival, ( C ) events-free survival and ( D ) overall survival note. The cut-off date for the analysis was August 31, 2022, with a median follow-up period of 29.6 months. BIRC, blinded independent review committee; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; FAS, full analysis set; GCB, germinal center B‐cell‐like; Hi-CHOP, zuberitamab plus CHOP; NE, not evaluable; R-CHOP, rituximab plus CHOP.

A

Duration of response

Figure 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme jump曲线 2:extreme jump曲线 2:extreme upward reversal
查看结果
B

Progression-free survival

Figure 3 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:extreme jump曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
C

Event-free survival

Figure 3 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

Overall survival

Figure 3 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:short span曲线 2:extreme jump曲线 2:extreme upward reversal
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Flowchart of the patients’ disposition. BIRC, blinded independent review committee; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; FAS, full analysis set; Hi-CHOP, zuberitamab plus CHOP; PPS, per-protocol set; SS, safety set; R-CHOP, rituximab plus CHOP.
非 KM Figure